Clinical Trial Update: Lenvatinib Plus PD-1 Antibody for Unresectable ICC [Phase 2]

View source ↗

Summary

A Phase 2 trial of lenvatinib plus a PD-1 antibody for unresectable intrahepatic cholangiocarcinoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Shi Ming | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: SUSPENDED